Gadobenate dimeglumine-enhanced liver MR imaging in cirrhotic patients: Quantitative and qualitative comparison of 1-hour and 3-hour delayed images

Journal of Magnetic Resonance Imaging

Volumn 33, Issue 4, 2011, Pages 889-897

  Jeong, Woo Kyoung ^a,b   Byun, Jae Ho ^a   Lee, Seung Soo ^a   Won, Hyung Jin ^a   Kim, Kyoung Won ^a   Shin, Yong Moon ^a   Kim, Pyo Nyun ^a   Lee, Moon Gyu ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Hanyang University Guri Hospital   (South Korea)

Author keywords

Gadobenate dimeglumine; Hepatocellular carcinoma; Liver cirrhosis; Magnetic resonance imaging

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GADOBENATE DIMEGLUMINE; INDOCYANINE GREEN;

1 HOUR DELAYED PHASE MAGNETIC RESONANCE IMAGE; 3 HOUR DELAYED PHASE MAGNETIC RESONANCE IMAGE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER SIZE; CHEMOEMBOLIZATION; COMPARATIVE EFFECTIVENESS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMAGE QUALITY; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TIME LAPSE IMAGING;

ADULT; AGED; CONTRAST MEDIA; FEMALE; FIBROSIS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953248348     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22492     Document Type: Article

References (20)

1. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999;6:282-291. (Pubitemid 32673373)
2. Kirchin M, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 1998;33:798-809. (Pubitemid 30247065)
3. Manfredi R, Maresca G, Baron RL, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 1999;9:704-710. (Pubitemid 29211165)
4. Kim YK, Lee JM, Kim CS. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 2004;14:5-13. (Pubitemid 38181049)
5. Del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology 2002;225:766-772. (Pubitemid 35387115)
6. Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2005;15:220-228.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236. (Pubitemid 43112690)
8. Marin D, Martino MD, Cuerrisi A, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology 2009;251:85-95.
9. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
10. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 2000;35:25-34. (Pubitemid 30033604)
11. Manfredi R, Maresca G, Baron RL, et al. Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 1998;8:862-867. (Pubitemid 28357594)
12. Marti-Bonmati L, Masia L, Casillas C, Ronchera-Oms CL, Torrijo C. Differentiation of healthy from cirrhotic livers: evaluation of paramagnetic images after contrast administration in magnetic resonance imaging. Invest Radiol 1996;31:768-773. (Pubitemid 26425421)
13. Fujita T, Ito K, Honjo K, Okazaki H, Matsumoto T, Matsunaga N. Hepatic parenchymal enhancement in the cirrhotic liver: evaluation by triple-phase dynamic MRI. Abdom Imaging 2002;27:29-33. (Pubitemid 36459858)
14. Planchamp C, Montet X, Frossard J-L, et al. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol 2005;40:187-194. (Pubitemid 40393229)
15. Sidhu MK, Muller HH, Aggeler J, Jones AL, Young SW. Manganese dipyridoxal diphosphate-enhanced magnetic resonance imaging in the evaluation of hepatocyte function. Invest Radiol 1993;28:903-910. (Pubitemid 24079757)
16. Marti-Bonmati L, Lonjedo E, Poyatos C, Casillas C. MnDPDP enhancement characteristics and differentiation between cirrhotic and noncirrhotic livers. Invest Radiol 1998;33:717-722.
17. Murakami T, Baron RL, Federle MP, et al. Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996;198:567-572.
18. Planchamp C, Gex-Fabry M, Becker CD, Pastor CM. Model-based analysis of Gd-BOPTA-induced MR signal intensity changes in cirrhotic rat livers. Invest Radiol 2007;42:513-521. (Pubitemid 46955246)
19. Ryeom HK, Kim SH, Kim JY, et al. Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol 2004;5:231-239.
20. de Haen C, Lorusso V, Luzzani F, Tirone P. Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat. Acad Radiol 1995;2:232-238.